Hikma Pharmaceuticals/£HIK
07:00
09:10
11:15
13:25
15:30
1D1W1MYTD1Y5YMAX
About Hikma Pharmaceuticals
Hikma Pharmaceuticals is a multinational pharmaceutical company headquartered in London, United Kingdom. It specializes in the development, manufacturing, and marketing of a broad portfolio of branded and non-branded generic and in-licensed pharmaceutical products. The company operates across three main segments: Injectables, Generics, and Branded, serving hospitals, pharmacies, and wholesalers. Hikma was founded in 1978 in Amman, Jordan, and has since expanded its operations globally, maintaining a significant presence in the Middle East and North Africa, the United States, and Europe. Its strategic positioning is supported by its extensive manufacturing capabilities and a strong commitment to quality and regulatory compliance.
Ticker
£HIK
Sector
Primary listing
LSE
Employees
9,500
Headquarters
Website
HIK Metrics
BasicAdvanced
£3.6B
13.14
£1.23
0.60
£0.60
3.74%
Price and volume
Market cap
£3.6B
Beta
0.6
52-week high
£23.60
52-week low
£16.07
Average daily volume
660K
Dividend rate
£0.60
Financial strength
Current ratio
1.244
Quick ratio
0.653
Long term debt to equity
33.007
Total debt to equity
61.074
Dividend payout ratio (TTM)
47.71%
Interest coverage (TTM)
8.17%
Profitability
EBITDA (TTM)
560.959
Gross margin (TTM)
43.03%
Net profit margin (TTM)
11.54%
Operating margin (TTM)
18.03%
Effective tax rate (TTM)
19.26%
Revenue per employee (TTM)
£249,640
Management effectiveness
Return on assets (TTM)
6.97%
Return on equity (TTM)
15.38%
Valuation
Price to earnings (TTM)
13.141
Price to revenue (TTM)
1.505
Price to book
1.4
Price to tangible book (TTM)
2.69
Price to free cash flow (TTM)
21.229
Free cash flow yield (TTM)
4.71%
Free cash flow per share (TTM)
0.758
Dividend yield (TTM)
3.74%
Growth
Revenue change (TTM)
6.60%
Earnings per share change (TTM)
31.16%
3-year revenue growth (CAGR)
8.04%
10-year revenue growth (CAGR)
8.22%
3-year earnings per share growth (CAGR)
3.66%
10-year earnings per share growth (CAGR)
3.22%
3-year dividend per share growth (CAGR)
15.16%
10-year dividend per share growth (CAGR)
12.44%
What the Analysts think about HIK
Analyst ratings (Buy, Hold, Sell) for Hikma Pharmaceuticals stock.
Bulls say / Bears say
Hikma is racing to launch generic versions of Novo Nordisk’s Ozempic and Wegovy once patents begin expiring from 2026, targeting a global weight-loss drug market valued at $80–140 billion and poised for high demand for lower-cost generics (FT.com).
Hikma’s injectables segment has treated over 800,000 patients with its technology converting IV medications into subcutaneous injections, underscoring strong partnership momentum and bolstering its injectables pipeline across oncology and autoimmune therapies (Bloomberg).
FT notes Hikma is the second-largest drugmaker by sales in the Middle East and North Africa, providing a stable revenue base and significant growth prospects in emerging markets where it faces limited competition (FT.com).
Hikma agreed to pay $50 million to settle a class action alleging it colluded to delay its generic Xyrem approval for the narcolepsy drug Xyrem, highlighting material litigation risk and potential further liabilities (Reuters).
The FDA’s declaration that the national shortage of branded Ozempic and Wegovy is over removes a key catalyst for generic copycats like Hikma, potentially slowing initial uptake of its planned semaglutide generics (Bloomberg).
The U.S. government’s new most-favored-nation drug pricing policy threatens to cap prices for branded drugs without generic competition, which could compress margins in Hikma’s Branded segment in key markets (Reuters).
Data summarised monthly by Lightyear AI. Last updated on 30 Aug 2025.
HIK Financial Performance
Revenues and expenses
HIK Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.
Capital at risk
Upcoming events
Sept18
Hikma Pharmaceuticals
DividendPayment
£0.265842Per share
FAQs
What’s the current market cap for Hikma Pharmaceuticals stock?
Hikma Pharmaceuticals (HIK) has a market cap of £3.6B as of September 16, 2025.
What is the P/E ratio for Hikma Pharmaceuticals stock?
The price to earnings (P/E) ratio for Hikma Pharmaceuticals (HIK) stock is 13.14 as of September 16, 2025.
Does Hikma Pharmaceuticals stock pay dividends?
Yes, the Hikma Pharmaceuticals (HIK) stock pays dividends to shareholders. As of September 16, 2025, the dividend rate is £0.60178 and the yield is 3.74%. Hikma Pharmaceuticals has a payout ratio of 47.71% on a trailing twelve-month basis.
When is the next Hikma Pharmaceuticals dividend payment date?
The next Hikma Pharmaceuticals (HIK) dividend payment is scheduled for September 18, 2025.
What is the beta indicator for Hikma Pharmaceuticals?
Hikma Pharmaceuticals (HIK) has a beta rating of 0.6. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.